Country
Denmark
Genmab A/S has stopped development of enapotamab vedotin, an antibody-drug conjugate being investigated for the treatment of solid tumours after early clinical data did not meet the company’s criteria.
Full text available to subscribers only. Click here for information on subscribing to MedNous.